Jerome Biollaz
Jerome Biollaz
Email verificata su
Citata da
Citata da
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
C Marzolini, A Telenti, LA Decosterd, G Greub, J Biollaz, T Buclin
Aids 15 (1), 71-75, 2001
Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients
M Rotger, S Colombo, H Furrer, G Bleiber, T Buclin, BL Lee, O Keiser, ...
Pharmacogenetics and genomics 15 (1), 1-5, 2005
Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection
C Csajka, C Marzolini, K Fattinger, LA Décosterd, J Fellay, A Telenti, ...
Clinical Pharmacology & Therapeutics 73 (1), 20-30, 2003
Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade.
J Biollaz, HR Brunner, I Gavras, B Waeber, H Gavras
Journal of cardiovascular pharmacology 4 (6), 966-972, 1982
Diet acids and alkalis influence calcium retention in bone
T Buclin, M Cosma, M Appenzeller, AF Jacquet, LA Decosterd, J Biollaz, ...
Osteoporosis International 12 (6), 493-499, 2001
Enalapril maleate and a lysine analogue (MK‐521): disposition in man.
EH Ulm, M Hichens, HJ Gomez, AE Till, E Hand, TC Vassil, J Biollaz, ...
British journal of clinical pharmacology 14 (3), 357-362, 1982
Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor" MK-421".
H Gavras, B Waeber, I Gavras, J Biollaz, HR Brunner, RO Davies
The Lancet 318 (8246), 543-547, 1981
Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist
A Munafo, Y Christen, J Nussberger, LY Shum, RM Borland, RJ Lee, ...
Clinical Pharmacology & Therapeutics 51 (5), 513-521, 1992
Population pharmacokinetics of imatinib and the role of α1‐acid glycoprotein
N Widmer, LA Decosterd, C Csajka, S Leyvraz, MA Duchosal, A Rosselet, ...
British journal of clinical pharmacology 62 (1), 97-112, 2006
Three new long‐acting converting‐enzyme inhibitors: relationship between plasma converting‐enzyme activity and response to angiotensin I
J Biollaz, M Burnier, GA Turini, DB Brunner, M Porchet, HJ Gomez, ...
Clinical Pharmacology & Therapeutics 29 (5), 665-670, 1981
Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects.
DB Brunner, G Desponds, J Biollaz, I Keller, F Ferber, H Gavras, ...
British journal of clinical pharmacology 11 (5), 461-467, 1981
Raised leptin concentations at high altitude associated with loss of appetite.
M Tschop, CJ Strasburger
The Lancet 352 (9134), 1119-1120, 1998
Pharmacogenetics‐based population pharmacokinetic analysis of efavirenz in HIV‐1‐infected individuals
M Arab‐Alameddine, J Di Iulio, T Buclin, M Rotger, R Lubomirov, ...
Clinical Pharmacology & Therapeutics 85 (5), 485-494, 2009
Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists
C Csajka, T Buclin, HR Brunner, J Biollaz
Clinical pharmacokinetics 32 (1), 1-29, 1997
Treating the individual hypertensive patient: considerations on dose, sequential monotherapy and drug combinations.
HR Brunner, J Menard, B Waeber, M Burnier, J Biollaz, J Nussberger, ...
Journal of hypertension 8 (1), 3-11; discussion 13, 1990
Enalapril maleate and a lysine analogue (MK‐521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system.
J Biollaz, JL Schelling, B Jacot des Combes, DB Brunner, G Desponds, ...
British journal of clinical pharmacology 14 (3), 363-368, 1982
Effect of dronedarone on renal function in healthy subjects
Y Tschuppert, T Buclin, LE Rothuizen, LA Decosterd, J Galleyrand, ...
British journal of clinical pharmacology 64 (6), 785-791, 2007
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor …
C Marzolini, A Telenti, T Buclin, J Biollaz, LA Decosterd
Journal of Chromatography B: Biomedical Sciences and Applications 740 (1), 43-58, 2000
Transplacental passage of protease inhibitors at delivery
C Marzolini, C Rudin, LA Decosterd, A Telenti, A Schreyer, J Biollaz, ...
Aids 16 (6), 889-893, 2002
Renal drug transporters and drug interactions
A Ivanyuk, F Livio, J Biollaz, T Buclin
Clinical pharmacokinetics 56 (8), 825-892, 2017
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20